• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Application value of whole-course health management for patients with nonvalvular atrial fibrillation with oral warfarin treatment.全程健康管理在非瓣膜性心房颤动患者口服华法林治疗中的应用价值
Am J Transl Res. 2022 May 15;14(5):3269-3277. eCollection 2022.
2
Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy: An Evidence-Based Analysis.长期口服抗凝治疗患者的即时检测国际标准化比值(INR)监测设备:一项基于证据的分析。
Ont Health Technol Assess Ser. 2009;9(12):1-114. Epub 2009 Sep 1.
3
Effect of suboptimal anticoagulation treatment with antiplatelet therapy and warfarin on clinical outcomes in patients with nonvalvular atrial fibrillation: A population-wide cohort study.抗血小板治疗与华法林联用的亚最佳抗凝治疗对非瓣膜性心房颤动患者临床结局的影响:一项全人群队列研究。
Heart Rhythm. 2016 Aug;13(8):1581-8. doi: 10.1016/j.hrthm.2016.03.049. Epub 2016 Mar 28.
4
Meta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age With Non-Valvular Atrial Fibrillation.评价低强度华法林治疗非瓣膜性心房颤动 >65 岁患者的疗效和安全性的荟萃分析。
Am J Cardiol. 2021 Mar 1;142:74-82. doi: 10.1016/j.amjcard.2020.12.001. Epub 2020 Dec 8.
5
The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US.美国针对心房颤动且有高卒中风险患者的抗凝管理服务的成本效益
Pharmacoeconomics. 2006;24(10):1021-33. doi: 10.2165/00019053-200624100-00009.
6
How well does the target INR level maintain in warfarin-treated patients with non-valvular atrial fibrillation?华法林治疗的非瓣膜性心房颤动患者的目标国际标准化比值(INR)水平维持得如何?
Yonsei Med J. 2009 Feb 28;50(1):83-8. doi: 10.3349/ymj.2009.50.1.83. Epub 2009 Feb 24.
7
Prior Anticoagulation and Short- or Long-Term Clinical Outcomes in Ischemic Stroke or Transient Ischemic Attack Patients With Nonvalvular Atrial Fibrillation.非瓣膜性心房颤动的缺血性卒中和短暂性脑缺血发作患者的预先抗凝和短期或长期临床结局。
J Am Heart Assoc. 2019 Feb 5;8(3):e010593. doi: 10.1161/JAHA.118.010593.
8
Out-of-range INR values and outcomes among new warfarin patients with non-valvular atrial fibrillation.非瓣膜性心房颤动新服用华法林患者的国际标准化比值(INR)值超出范围情况及预后
Int J Clin Pharm. 2015 Feb;37(1):53-9. doi: 10.1007/s11096-014-0038-3. Epub 2014 Nov 27.
9
A predictive study of multivariate factors affecting goal attainment of INR after anticoagulation in patients with nonvalvular atrial fibrillation.多因素预测分析非瓣膜性心房颤动患者抗凝治疗后国际标准化比值(INR)达标的影响因素。
Ann Palliat Med. 2021 Apr;10(4):4532-4538. doi: 10.21037/apm-21-549.
10
Relation of Stroke and Bleeding Risk Profiles to Efficacy and Safety of Edoxaban for Cardioversion of Atrial Fibrillation (from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation [ENSURE-AF] Study).房颤患者电复律中新型口服抗凝剂(NOACs)与华法林的疗效和安全性比较(来自新型口服抗凝剂 Edoxaban 与华法林在房颤电复律患者中疗效和安全性的评估 [ENSURE-AF] 研究)
Am J Cardiol. 2018 Jan 15;121(2):193-198. doi: 10.1016/j.amjcard.2017.10.008. Epub 2017 Nov 20.

引用本文的文献

1
Standardized community management on the diagnosis, treatment, and risk factors control for non-valvular atrial fibrillation in elderly patients.老年非瓣膜性心房颤动患者的诊断、治疗和危险因素控制的规范化社区管理。
BMC Prim Care. 2023 Nov 30;24(1):257. doi: 10.1186/s12875-023-02207-1.

本文引用的文献

1
Risk of atrial fibrillation in athletes: a systematic review and meta-analysis.运动员心房颤动风险:系统评价和荟萃分析。
Br J Sports Med. 2021 Nov;55(21):1233-1238. doi: 10.1136/bjsports-2021-103994. Epub 2021 Jul 12.
2
Dialysis Mode and Associated Outcomes in Patients With End-Stage Renal Disease and Atrial Fibrillation: A 14-Year Nationwide Cohort Study.终末期肾病伴心房颤动患者的透析模式及相关结局:一项长达 14 年的全国性队列研究。
J Am Heart Assoc. 2021 Jun 15;10(12):e019596. doi: 10.1161/JAHA.120.019596. Epub 2021 Jun 2.
3
Association between use of amiodarone for non-valvular atrial fibrillation and patient survival: from the prospective China Atrial Fibrillation Registry.胺碘酮治疗非瓣膜性心房颤动与患者生存的关系:来自前瞻性中国心房颤动注册研究。
Chin Med J (Engl). 2020 Dec 1;134(3):309-317. doi: 10.1097/CM9.0000000000001270.
4
[Therapeutic management of nonvalvular atrial fibrillation].
Herz. 2020 Sep;45(6):603-616. doi: 10.1007/s00059-020-04960-w.
5
Rivaroxaban Versus Warfarin in African American Patients with Nonvalvular Atrial Fibrillation.利伐沙班与华法林在非裔美国患者中非瓣膜性心房颤动中的比较。
J Natl Med Assoc. 2020 Aug;112(4):395-401. doi: 10.1016/j.jnma.2020.04.014. Epub 2020 May 31.
6
The effect of warfarin knowledge on anticoagulation control among patients with heart valve replacement.华法林知识对心脏瓣膜置换患者抗凝控制的影响。
Int J Clin Pharm. 2020 Jun;42(3):861-870. doi: 10.1007/s11096-020-01043-y. Epub 2020 May 15.
7
Audit of NICE compliance with warfarin for non-valvular atrial fibrillation on admission to healthcare for older people wards in a university teaching hospital.对某大学教学医院老年病房收治的非瓣膜性心房颤动患者使用华法林情况进行的英国国家卫生与临床优化研究所(NICE)合规性审计。
Clin Med (Lond). 2020 Mar;20(Suppl 2):s19. doi: 10.7861/clinmed.20-2-s19.
8
Comparison of Healthcare Resource Utilization and Costs between Rivaroxaban and Warfarin for Nonvalvular Atrial Fibrillation in a Skilled Nursing Facility Setting.在熟练护理机构环境中,比较利伐沙班与华法林在非瓣膜性心房颤动中的医疗资源利用和成本。
Drugs Aging. 2020 Apr;37(4):281-289. doi: 10.1007/s40266-019-00737-x.
9
Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin.利伐沙班与华法林治疗心房颤动患者的卒中风险和死亡率。
Stroke. 2020 Feb;51(2):549-555. doi: 10.1161/STROKEAHA.119.025554. Epub 2019 Dec 31.
10
Healthcare resource utilization and costs among nonvalvular atrial fibrillation patients initiating rivaroxaban or warfarin in skilled nursing facilities: a retrospective cohort study.在熟练护理设施中启动利伐沙班或华法林的非瓣膜性心房颤动患者的医疗资源利用和成本:一项回顾性队列研究。
Curr Med Res Opin. 2020 Apr;36(4):529-536. doi: 10.1080/03007995.2019.1706464. Epub 2020 Jan 9.

全程健康管理在非瓣膜性心房颤动患者口服华法林治疗中的应用价值

Application value of whole-course health management for patients with nonvalvular atrial fibrillation with oral warfarin treatment.

作者信息

Zhang Min, Chen Jianjing, Gao Chunmei, Gu Shunzhong, Yang Ping, Xu Zhenlan

机构信息

Department of Cardiology, Hai'an People's Hospital, Jiangsu Province Hai'an 226600, Jiangsu Province, China.

Libao Central Health Cente, Hai'an City, Jiangsu Province Hai'an 226600, Jiangsu Province, China.

出版信息

Am J Transl Res. 2022 May 15;14(5):3269-3277. eCollection 2022.

PMID:35702076
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9185060/
Abstract

OBJECTIVE

To explore the effect of the whole-process health management model on the compliance of oral warfarin treatment in patients with non-valvular atrial fibrillation in primary hospitals.

METHODS

We retrospectively analyzed the clinical data of 130 patients with non-valvular atrial fibrillation treated in the Department of Cardiovascular Medicine, Hai'an People's Hospital from January 2019 to December 2019. Among them, 63 patients who received routine continuing care were included in the control group, and 67 patients treated with whole-course health management model of primary hospitals were included in the observation group. The two groups were compared in terms of the following parameters: Warfarin anticoagulation knowledge, medication compliance, compliance rate (international normalized ratio, INR) monitoring, bleeding events (gingival bleeding, subcutaneous bleeding, gastrointestinal bleeding, etc.), embolic events (vascular thrombosis), negative emotions before and after management, and patient satisfaction. Logistic analysis was used to analyze independent risk factors affecting the effect of warfarin anticoagulation in patients with non-valvular atrial fibrillation.

RESULTS

Compared with the control group, the warfarin anticoagulation knowledge, medication compliance, and INR compliance rate of the observation group were significantly higher, and the incidence of adverse events was significantly lower. Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS) scores were not significantly different between the two groups before management. After management, SAS and SDS scores decreased significantly in both groups, and were lower in the observation group compared with the control group. The management satisfaction was also significantly higher in the observation group.

CONCLUSION

Compared with the conventional continuation care model, the whole-process management in primary hospitals can improve patients' compliance with medical advice and treatment efficacy, with lower risk of bleeding and higher patient satisfaction, providing a better option for the out-of-hospital management of anticoagulation for non-valvular atrial fibrillation patients. Age, hypertension, diabetes, knowledge of warfarin anticoagulation and medication compliance were independent risk factors for the effect of warfarin anticoagulation in patients with non-valvular atrial fibrillation.

摘要

目的

探讨全程健康管理模式对基层医院非瓣膜性心房颤动患者口服华法林治疗依从性的影响。

方法

回顾性分析2019年1月至2019年12月在海安市人民医院心血管内科治疗的130例非瓣膜性心房颤动患者的临床资料。其中,63例接受常规延续性护理的患者纳入对照组,67例采用基层医院全程健康管理模式治疗的患者纳入观察组。比较两组以下指标:华法林抗凝知识、用药依从性、达标率(国际标准化比值,INR)监测、出血事件(牙龈出血、皮下出血、胃肠道出血等)、栓塞事件(血管血栓形成)、管理前后的负面情绪以及患者满意度。采用Logistic分析影响非瓣膜性心房颤动患者华法林抗凝效果的独立危险因素。

结果

与对照组相比,观察组的华法林抗凝知识、用药依从性及INR达标率显著更高,不良事件发生率显著更低。两组管理前的焦虑自评量表(SAS)和抑郁自评量表(SDS)评分差异无统计学意义。管理后,两组的SAS和SDS评分均显著降低,且观察组低于对照组。观察组的管理满意度也显著更高。

结论

与传统延续性护理模式相比,基层医院的全程管理可提高患者的医嘱依从性和治疗效果,出血风险更低,患者满意度更高,为非瓣膜性心房颤动患者院外抗凝管理提供了更好的选择。年龄、高血压、糖尿病、华法林抗凝知识及用药依从性是非瓣膜性心房颤动患者华法林抗凝效果的独立危险因素。